Dose Escalation Study of the Combination of ZD6474, Gemcitabine and Capecitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma

Trial Profile

Dose Escalation Study of the Combination of ZD6474, Gemcitabine and Capecitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Capecitabine (Primary) ; Gemcitabine (Primary) ; Vandetanib (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Apr 2009 Planned end date changed from 1 Jan 2009 to 1 Jun 2009 as reported by ClinicalTrials.gov.
    • 12 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top